专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011020089A3 TARGET GENES FOR CANCER THERAPY 审中-公开
标题翻译：癌症治疗的靶基因
公开(公告)号：WO2011020089A3
公开(公告)日：2011-12-15
申请号：PCT/US2010045600
申请日：2010-08-16
申请人： ORDWAY RES INST INC , RONINSON IGOR B , SHTUTMAN MICHAEL
发明人： RONINSON IGOR B , SHTUTMAN MICHAEL
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178
摘要： The invention provides new gene targets for cancer chemotherapy, their use in assays for identifying new small molecule cancer chemotherapeutic agents, methods for inhibiting cancer cell growth comprising contacting a cell with a gene expression blocking agent that inhibits the expression of such genes and methods for therapeutic treatment of cancer in a mammal, comprising administering to the mammal such a gene expression blocking agent. A preferred gene target is coatomer protein zeta-1 subunit (COPZl).
摘要翻译：本发明提供用于癌症化疗的新基因靶标，它们在鉴定新型小分子癌症化疗剂的测定中的用途，抑制癌细胞生长的方法，包括使细胞与抑制此类基因表达的基因表达阻断剂接触，以及治疗方法治疗哺乳动物中的癌症，所述方法包括向所述哺乳动物施用这种基因表达阻断剂。优选的基因靶标是衣壳蛋白ζ-1亚基（COPZ1）。

2. 发明申请

WO2005091716A2 ANNEXIN II AND USES THEREOF 审中-公开
标题翻译：附件二及其用途
公开(公告)号：WO2005091716A2
公开(公告)日：2005-10-06
申请号：PCT/IL2005000342
申请日：2005-03-27
申请人： QUARK BIOTECH INC , FUJISAWA PHARMACEUTICAL CO , FEINSTEIN ELENA , METT IGOR , SHTUTMAN MICHAEL
发明人： FEINSTEIN ELENA , METT IGOR , SHTUTMAN MICHAEL
IPC分类号： A61K31/405 , A61K31/7088 , A61K48/00 , C12N15/113
CPC分类号： A61K31/405 , A61K31/7088 , A61K33/26 , A61K48/00 , C12N15/113 , C12N2310/14
摘要： The present invention relates to the field of diagnosis and treatment of neurodegenerative diseases, ischemic events, and central nervous system injury, and provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. The present invention in particular relates to the discovery that the expression of Annexin II is involved in apoptosis induced by oxidative stress, and that anti-sense Annexin II RNA and Annexin II siRNA protected the cells from this apoptosis. Thus Annexin II inhibitors prevent the damage caused by said ischemic event.
摘要翻译：本发明涉及神经变性疾病，缺血事件和中枢神经系统损伤的诊断和治疗领域，并提供组织和方法，用于缓解或减少与损伤的神经元组织相关的症状和体征，无论是由组织创伤造成的，或者来自慢性或急性退行性变化。本发明特别涉及膜联蛋白II的表达参与由氧化应激诱导的凋亡的发现，反义膜联蛋白II RNA和膜联蛋白II siRNA保护细胞免于细胞凋亡。因此，膜联蛋白II抑制剂可防止由所述缺血事件引起的损伤。

3. 发明申请

WO0218537A3 METHODS OF ISOLATING GENES ENCODING PROTEINS OF SPECIFIC FUNCTION AND OF SCREENING FOR PHARMACEUTICALLY ACTIVE AGENTS 审中-公开
标题翻译：分离编码具有特定功能的蛋白质和筛选药物活性剂的基因的方法
公开(公告)号：WO0218537A3
公开(公告)日：2002-07-25
申请号：PCT/IL0100813
申请日：2001-08-29
申请人： YEDA RES & DEV , GEIGER BENJAMIN , KAM ZVI , ZAMIR ELI , BERSHADSKY ALEXANDER , SHTUTMAN MICHAEL , BEN-ZE EV AVRI
发明人： GEIGER BENJAMIN , KAM ZVI , ZAMIR ELI , BERSHADSKY ALEXANDER , SHTUTMAN MICHAEL , BEN-ZE EV AVRI
IPC分类号： C12N5/10 , C12N15/09 , C12N15/10 , C12Q1/02 , G01N33/15 , G01N33/50 , C12Q1/68 , C07H21/02 , C12N15/00 , G01N33/53
CPC分类号： C12N15/1086 , C12N15/1051 , G01N33/5076
摘要： A method of isolating polynucleotides encoding polypeptides affecting an organization of a subcellular organelle or structure of interest is provided. The method comprises: (a) expressing within a plurality of cells an expression library including a plurality of expression constructs each encoding a polypeptide of interest; (b) highlighting the subcellular organelle or structure of interest of the plurality of cells; and (c) isolating a cell or cells of the plurality of cells in which a cellular distribution and/or level of the subcellular organelle or structure of interest is altered to thereby isolate polypeptides capable of affecting the organization of the subcellular organelle or structure of interest.
摘要翻译：提供了分离编码影响亚细胞器或感兴趣结构组织的多肽的多核苷酸的方法。该方法包括：（a）在多个细胞内表达包含多个表达构建体的表达文库，每个表达构建体编码感兴趣的多肽; （b）突出显示多个细胞的亚细胞器或感兴趣的结构; 和（c）分离其中细胞分布和/或亚细胞器或感兴趣结构的水平被改变的多个细胞中的一个或多个细胞，从而分离能够影响亚细胞器或感兴趣结构的组织的多肽。

4. 发明申请

WO2005041857A3 BONE MORPHOGENETIC PROTEIN (BMP) 2A AND USES THEREOF 审中-公开
标题翻译：骨形态蛋白（BMP）2A及其用途
公开(公告)号：WO2005041857A3
公开(公告)日：2007-07-26
申请号：PCT/IL2004000924
申请日：2004-10-06
申请人： QUARK BIOTECH INC , ASTELLAS PHARMA INC , FEINSTEIN ELENA , METT IGOR , GORODIN SVETLANA , SHTUTMAN MICHAEL
发明人： FEINSTEIN ELENA , METT IGOR , GORODIN SVETLANA , SHTUTMAN MICHAEL
IPC分类号： C07H21/04 , A61K20060101 , C12N15/113
CPC分类号： C12N15/1136 , C12N2310/11 , C12N2310/111 , C12N2310/14
摘要： The present invention provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. In particular, some embodiments of the present invention provide one or more pharmaceutical compositions comprising as an active ingredient a BMP2A inhibitor further comprising a pharmaceutically acceptable diluent or carrier. An additional embodiment provides a method for reducing damage to the central nervous system in a patient who has suffered an injury to the central nervous system, comprising administering to the patient a pharmaceutical composition in a dosage sufficient to reduce the damage. Yet another embodiment provides of the use of a BMP2A inhibitor for the preparation of a medicament for promoting or enhancing recovery in a patient who has suffered an injury to the central nervous system. Preferable inhibitors according to some embodiments of the invention are siRNA molecules and neutralizing antibodies. An additional embodiment provides a method for identifying a chemical compound that modulates apoptosis. Further, a process for diagnosing a neurodegenrative disease or an ischemic event in a subject is provided. The preferred methods, materials, and examples that will now be described are illustrative only and are not intended to be limiting; materials and methods similar or equivalent to those described herein can be used in practice or testing of the invention. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
摘要翻译：本发明提供用于缓解或减少与损伤的神经元组织相关的症状和体征的组合物和方法，无论是由组织创伤引起的，还是由慢性或急性退行性变化引起的。特别地，本发明的一些实施方案提供一种或多种药物组合物，其包含作为活性成分的进一步包含药学上可接受的稀释剂或载体的BMP2A抑制剂。另一个实施方案提供了减轻对中枢神经系统损伤的患者中的中枢神经系统的损伤的方法，包括以足以减少损伤的剂量向患者施用药物组合物。另一个实施方案提供了BMP2A抑制剂用于制备用于促进或增强患有中枢神经系统损伤的患者的恢复的药物的用途。根据本发明一些实施方案的优选的抑制剂是siRNA分子和中和抗体。另外的实施方案提供了鉴定调节细胞凋亡的化合物的方法。此外，提供了用于诊断受试者中的神经发生性疾病或缺血事件的方法。现在将要描述的优选方法，材料和实施例仅是说明性的而不是限制性的; 可以在本发明的实践或测试中使用与本文所述类似或等同的材料和方法。从以下详细描述和权利要求书中，本发明的其它特征和优点将变得显而易见。

5. 发明申请

WO2005091716A8 ANNEXIN II AND USES THEREOF 审中-公开
标题翻译：附件二及其用途
公开(公告)号：WO2005091716A8
公开(公告)日：2007-05-03
申请号：PCT/IL2005000342
申请日：2005-03-27
申请人： QUARK BIOTECH INC , ASTELLAS PHARMA INC , FEINSTEIN ELENA , METT IGOR , SHTUTMAN MICHAEL
发明人： FEINSTEIN ELENA , METT IGOR , SHTUTMAN MICHAEL
IPC分类号： A61K31/70 , A61K31/405 , A61K31/7088 , A61K48/00 , C07H21/02 , C07H21/04 , C12N15/00 , C12N15/113 , C12Q1/68
CPC分类号： A61K31/405 , A61K31/7088 , A61K33/26 , A61K48/00 , C12N15/113 , C12N2310/14
摘要： The present invention relates to the field of diagnosis and treatment of neurodegenerative diseases, ischemic events, and central nervous system injury, and provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. The present invention in particular relates to the discovery that the expression of Annexin II is involved in apoptosis induced by oxidative stress, and that anti-sense Annexin II RNA and Annexin II siRNA protected the cells from this apoptosis. Thus Annexin II inhibitors prevent the damage caused by said ischemic event.
摘要翻译：本发明涉及神经变性疾病，缺血事件和中枢神经系统损伤的诊断和治疗领域，并且提供了用于缓解或减少与损伤的神经元组织相关的症状和体征的组合物和方法，无论是由组织创伤引起的，还是从慢性或急性退行性变化。本发明特别涉及膜联蛋白II的表达参与由氧化应激诱导的细胞凋亡的发现，并且反义膜联蛋白II RNA和Annexin II siRNA保护细胞免于细胞凋亡。因此，膜联蛋白II抑制剂可防止由所述缺血事件引起的损伤。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式